Literature DB >> 1423276

Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13.

A Banerjee1, H J Xu, S X Hu, D Araujo, R Takahashi, E J Stanbridge, W F Benedict.   

Abstract

Functional loss of the retinoblastoma (RB) gene has been implicated in the initiation or progression of several human tumor types including cancer of the eye, bone, bladder, and prostate. To examine the consequence of adding one RB allele containing its normal regulatory elements back into representative examples of each of these cancer types, as well as to compare the results to those previously reported using various RB complementary DNA constructs, a neomycin resistant marked 13 chromosome was transferred by microcell fusion. Several attempts to obtain RB positive osteosarcoma cells failed. In addition, only one RB positive retinoblastoma clone was isolated. This clone contained many large cells, could not be maintained in long-term culture, and produced only RB negative tumors. Three RB positive bladder cancer cell clones were obtained, all of which grew slower in culture than their RB negative parental counterpart and did not form colonies in soft agar. Tumorigenicity was markedly suppressed in these clones. One clone yielded no tumors, and the other 2 clones produced only one small tumor each, both of which were RB negative. In contrast, the 2 RB positive prostate cancer cell clones isolated had no differences in their cell culture growth properties, including growth in soft agar compared to the parental cells. One of the clones was nontumorigenic, while the other clone produced 4 small tumors, all of which were RB positive. These results indicate that the transfer of one RB allele by microcell transfer produces different levels of growth inhibition as well as tumor suppression, depending on the cell type examined. In the case of prostate cancer, the function of the RB gene in tumor suppression appears to be independent from its growth regulatory function, since no growth inhibition in cell culture was noted in these cells, although tumor suppression was significant.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423276

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 2.  Tumor suppressor genes in molecular medicine.

Authors:  F Hoppe-Seyler; K Butz
Journal:  Clin Investig       Date:  1994-08

Review 3.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells.

Authors:  Y Zhou; J Li; K Xu; S X Hu; W F Benedict; H J Xu
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  Gene expression profiling elucidates a specific role for RARgamma in the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells.

Authors:  Dan Su; Lorraine J Gudas
Journal:  Biochem Pharmacol       Date:  2007-11-22       Impact factor: 5.858

Review 6.  The cell cycle and the retinoblastoma protein family.

Authors:  M E Ewen
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

7.  Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma.

Authors:  S Vesalainen; P Lipponen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer.

Authors:  P K Lipponen; T J Liukkonen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells.

Authors:  David Cobrinik; Richard O Francis; David H Abramson; Thomas C Lee
Journal:  Mol Cancer       Date:  2006-12-12       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.